Serum soluble Fas ligand is a severity and mortality prognostic marker for COVID-19 patients

被引:14
|
作者
Saleki, Kiarash [1 ,2 ,3 ,4 ]
Shirzad, Moein [1 ,2 ,4 ]
Javanian, Mostafa [5 ]
Mohammadkhani, Sheyda [2 ]
Alijani, Mohammad Hossein [2 ]
Miri, Niloufarsadat [1 ]
Oladnabi, Morteza [6 ]
Azadmehr, Abbas [1 ,4 ,7 ]
机构
[1] Babol Univ Med Sci, Hlth Res Inst, Cellular & Mol Biol Res Ctr, Babol, Iran
[2] Babol Univ Med Sci, Student Res Comm, Babol, Iran
[3] Babol Univ Med Sci, USERN Off, Babol, Iran
[4] Natl Elite Fdn, Mazandaran Prov Branch, Mazandaran, Iran
[5] Babol Univ Med Sci, Hlth Res Inst, Infect Dis & Trop Med Res Ctr, Babol, Iran
[6] Golestan Univ Med Sci, Ischem Disorders Res Ctr, Gorgan, Iran
[7] Babol Univ Med Sci, Immunol Dept, Babol, Iran
来源
FRONTIERS IN IMMUNOLOGY | 2022年 / 13卷
关键词
COVID-19; hyperinflammation; Fas; viral Immunology; immunoinformatics; AA FORCE-FIELD; EXPRESSION; APOPTOSIS; INJURY; ACTIVATION; VIRUS; GENE;
D O I
10.3389/fimmu.2022.947401
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Finding cytokine storm initiator factors associated with uncontrolled inflammatory immune response is necessary in COVID-19 patients. The aim was the identification of Fas/Fas Ligand (FasL) role in lung involvement and mortality of COVID-19 patients. In this case-control study, mild (outpatient), moderate (hospitalized), and severe (ICU) COVID-19 patients and healthy subjects were investigated. RNA isolated from PBMCs for cDNA synthesis and expression of mFas/mFasL mRNA was evaluated by RT-PCR. Serum sFas/sFasL protein by ELISA and severity of lung involvement by CT-scan were evaluated. Also, we docked Fas and FasL via Bioinformatics software (in silico) to predict the best-fit Fas/FasL complex and performed molecular dynamics simulation (MDS) in hyponatremia and fever (COVID-19 patients), and healthy conditions. mFasL expression was increased in moderate and severe COVID-19 patients compared to the control group. Moreover, mFas expression showed an inverse correlation with myalgia symptom in COVID-19 patients. Elevation of sFasL protein in serum was associated with reduced lung injury and mortality. Bioinformatics analysis confirmed that blood profile alterations of COVID-19 patients, such as fever and hyponatremia could affect Fas/FasL complex interactions. Our translational findings showed that decreased sFasL is associated with lung involvement; severity and mortality in COVID-19 patients. We think that sFasL is a mediator of neutrophilia and lymphopenia in COVID-19. However, additional investigation is suggested. This is the first report describing that the serum sFasL protein is a severity and mortality prognostic marker for the clinical management of COVID-19 patients.
引用
收藏
页数:20
相关论文
共 50 条
  • [41] Severity, mortality, and incidence of venous thromboembolism in COVID-19 patients
    Ali, Ahmed Al-Husseiny
    Assal, Hebatallah Hany
    Ismail, Mohamed Said
    Mashaly, Basem Abdelmonem
    Elwafa, Gihan Saad Abo
    EGYPTIAN JOURNAL OF BRONCHOLOGY, 2024, 18 (01)
  • [42] Lymphocyte subsets as a predictor of severity and mortality in COVID-19 patients
    Appice, C.
    Belfiore, A.
    Binetti, M.
    Bonfrate, L.
    Campanale, G. A.
    Cicala, L.
    D'Alitto, F.
    Di Ciaula, A.
    Loiodice, R.
    Mallardi, C.
    Noto, A.
    Passerini, F.
    Pugliese, F. Prigigallo
    Vitariello, G.
    Di Girolamo, A.
    Portincasa, P.
    Palmieri, V. O.
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2022, 52
  • [43] Serum levels of soluble Fas ligand as a tumor marker in patients with early and advanced gastric cancer.
    Chinery, R
    Song, SY
    GASTROENTEROLOGY, 2000, 118 (04) : A257 - A257
  • [44] Serum soluble toll-like receptor 4 and risk for clinical severity in COVID-19 patients
    Maha E. Houssen
    Marwa O. Elmaria
    Dina Badr
    Rasha El-Mahdy
    Mayada A. Ghannam
    Shaimaa El-Ashwah
    May Denewer
    Metwaly Ibrahim Mortada
    Pneumonia, 16
  • [45] Serum soluble toll-like receptor 4 and risk for clinical severity in COVID-19 patients
    Houssen, Maha E.
    Elmaria, Marwa O.
    Badr, Dina
    El-Mahdy, Rasha
    Ghannam, Mayada A.
    El-Ashwah, Shaimaa
    Denewer, May
    Mortada, Metwaly Ibrahim
    PNEUMONIA, 2024, 16 (01)
  • [46] ?Pneumomediastinum: A marker of severity in Covid-19 disease?
    Khaire, Nivedita
    Deshmukh, Sonali
    Agarwal, Esha
    Mahale, Nilesh
    Khaladkar, Sanjay
    Desai, Sanjay
    Kulkarni, Ashwini
    HELIYON, 2023, 9 (01)
  • [47] Significance of serum soluble Fas ligand in patients with bladder carcinoma
    Mizutani, Y
    Hongo, F
    Sato, N
    Ogawa, O
    Yoshida, O
    Miki, T
    CANCER, 2001, 92 (02) : 287 - 293
  • [48] Severity of COVID-19 Patients Predicted by Serum Sphingolipids Signature
    Torretta, Enrica
    Garziano, Micaela
    Poliseno, Mariacristina
    Capitanio, Daniele
    Biasin, Mara
    Santantonio, Teresa Antonia
    Clerici, Mario
    Lo Caputo, Sergio
    Trabattoni, Daria
    Gelfi, Cecilia
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (19)
  • [49] Fibronectin as a Marker of Disease Severity in Critically Ill COVID-19 Patients
    Lemanska-Perek, Anna
    Krzyzanowska-Golab, Dorota
    Dragan, Barbara
    Tyszko, Maciej
    Adamik, Barbara
    CELLS, 2022, 11 (09)
  • [50] The impact of Prognostic Nutritional Index on mortality in patients with COVID-19
    Nergiz, Sebnem
    Ozturk, Onder
    NUTRITION & FOOD SCIENCE, 2024, 54 (07): : 1259 - 1267